1 Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON M5G 2M9, Canada; Optimal Cancer Care Alliance, Ann Arbor, MI, USA. Electronic address: ian.tannock@uhn.ca.
2 International Drug Development Institute, Louvain-la-Neuve, Belgium; I-BioStat, Hasselt University, Hasselt, Belgium.
3 International Drug Development Institute, Louvain-la-Neuve, Belgium.
4 Department of Oncology, University of Cambridge, Cambridge, UK.
5 Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Davidoff Cancer Center, Rabin Medical Center, Israel; Clalit Health Services, Tel Aviv, Israel (DAG); Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
6 Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Department of Medicine, Section of Hematology/ Oncology, The University of Chicago, Chicago, IL, USA.
7 Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
8 Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/ Netherlands Cancer Institute, Amsterdam, Netherlands; University of Amsterdam, Amsterdam, Netherlands.
9 Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Veterans Affairs Center for Clinical Management Research, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Division of Oncology and Lung Precision Oncology Program, University of Michigan Division of Hematology/Oncology, Rogel Cancer Center, Institute for Health Policy and Innovation, and Center for Global Health Equity, Ann Arbor, MI, USA.